|
Lead Discovery Initiative
| |
Applications
will be accepted on a continuous basis and will be reviewed
once each month. |
In conjunction with the Keck-UW Carbone Cancer Center Small Molecule
Screening Facility (SMSF), WARF is launching a new initiative
for assay development and small molecule screening. The Lead Discovery
Initiative addresses the development and application of high-throughput
screening assays to the identification of small molecules that
play a role in pathway modulation and have potential for future
commercial development.
Researchers who have characterized putative regulatory elements
or drug targets in any therapeutic indication are encouraged to
apply. The program is also open to researchers who have already
begun to conduct small molecule screens of putative drug targets
through initial work at the SMSF, but lack the funds to develop
structure activity relationships (SAR) for lead candidates.
Work under the Lead Discovery Initiative will be carried out at
the SMSF, with WARF funding administered directly to SMSF. The
program is designed to assist in assay development, screening
the existing compound library, and ultimately, obtaining expanded
compound libraries from commercial sources to further develop
SAR. Applications will be evaluated on a monthly basis by a core
team comprising representatives from the School of Pharmacy, the
SMSF and WARF.
All UW researchers are eligible to apply in conjunction with a
principal investigator. Applicants must have submitted a WARF Invention
Disclosure Report (IDR)
prior to, or may do so at the same time as their LDI
application.
Additional details regarding the initiative can be found in the Request
for Applications.
Questions about the initiatives should be directed to:
Laura M. Heisler, PhD
Manager, WARF Strategic Technology Enhancement Program
608-261-1022
For questions concerning the UWCCC SMSF or specific SMSF services,
contact
Noël Peters MS
Screen Facility Director
608.265.8687
|
|
